Development of replication-competent adenovirus based vaccine vectors

por Abbink, P, Maxfield, LF, Barouch, DH
Publicado 2012

Adenovirus serotype 26 utilizes CD46 as primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys

por Li, H, Rhee, EG, Masek-Hammerman, K, Teigler, JE, Abbink, P, Barouch, DH
Publicado 2012

Development of a novel simian adenovirus 24 based vaccine vector

por Abbink, P, Bradley, RR, Ball, F, Ng'ang'a, D, Borducchi, E, Barouch, DH
Publicado 2012

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector

por Baden, LR, Dolin, R, O'Brien, KL, Abbink, P, La Porte, A, Seaman, MS, Choi, E, Tucker, R, Weitjens, M, Pau, MG, Goudsmit, J, Barouch, DH
Publicado 2009

NS1 DNA vaccination protects against Zika infection through T cell–mediated immunity in immunocompetent mice

por Grubor-Bauk, B., Wijesundara, D. K., Masavuli, M., Abbink, P., Peterson, R. L., Prow, N. A., Larocca, R. A., Mekonnen, Z. A., Shrestha, A., Eyre, N. S., Beard, M. R., Gummow, J., Carr, J., Robertson, S. A., Hayball, J. D., Barouch, D. H., Gowans, E. J.
Publicado 2019